NEXT GENERATION SEQUENCING OF NON‐MUSCLE INVASIVE BLADDER CANCER REVEALS POTENTIAL BIOMARKERS AND RATIONAL THERAPEUTIC TARGETS: PD48‐11

[1]  Shuye Liu,et al.  The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients , 2019, Medicine.

[2]  M. Berger,et al.  Genomic characterization of response to chemoradiation in urothelial bladder cancer , 2016, Cancer.

[3]  M. Berger,et al.  Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[5]  N. Schultz,et al.  Genomic Characterization of Upper Tract Urothelial Carcinoma. , 2015, European urology.

[6]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[7]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[8]  Ye Tian,et al.  p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive Bladder Cancers Treated with Bacillus Calmette–Guérin: A Meta-Analysis , 2015, PloS one.

[9]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[10]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[11]  N. Schultz,et al.  Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. , 2015, European urology.

[12]  M. Knowles,et al.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity , 2014, Nature Reviews Cancer.

[13]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[14]  T. Ørntoft,et al.  Mutational context and diverse clonal development in early and late bladder cancer. , 2014, Cell reports.

[15]  Peter Donnelly,et al.  Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden , 2014, Nature Communications.

[16]  M. Glickman,et al.  The mechanism of action of BCG therapy for bladder cancer—a current perspective , 2014, Nature Reviews Urology.

[17]  M. Knowles,et al.  Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. , 2014, European urology.

[18]  T. Ørntoft,et al.  Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. , 2014, European urology.

[19]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[20]  C. Taylor,et al.  Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes , 2013, Human molecular genetics.

[21]  A. Valencia,et al.  Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy , 2013, Nature Genetics.

[22]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[23]  Karim Chamie,et al.  Recurrence of high‐risk bladder cancer: A population‐based analysis , 2013, Cancer.

[24]  N. Malats,et al.  ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors , 2013, PloS one.

[25]  M. Knowles,et al.  Oncogenic FGFR3 gene fusions in bladder cancer , 2012, Human molecular genetics.

[26]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[27]  Hongtao Yu,et al.  Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer , 2011, Science.

[28]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[29]  C. Marsit,et al.  Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States , 2008, Scandinavian journal of urology and nephrology.

[30]  J. Bartek,et al.  DNA Damage Response as an Anti-Cancer Barrier: Damage Threshold and the Concept of 'Conditional Haploinsufficiency' , 2007, Cell cycle.

[31]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[32]  J. Alfred Witjes,et al.  Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. , 2011, European urology.